October 28, 2021, Singapore – Evive Biotech, a global biologics company developing novel biologic therapies, today announces the appointment of Mr. Denny Hou as VP, Global Medical Research. Mr. Hou has more than 15 years of medical research experience and joins Evive Biotech to provide leadership and management for all medical research activities, including the development of clinical research plans, study protocols, investigator brochures, and clinical study reports.

Prior to joining Evive Biotech, Mr. Hou’s career was spent in multiple therapeutic areas including immuno-oncology, ophthalmology, respiratory disease, cardiovascular disease, and diabetes. Prior to joining Evive, he worked for Bayer HealthCare, Innovent and Kang Hong where he had rich practical experience in clinical development and medical affairs. Mr. Hou graduated from Peking University’s School of Medicine, with a degree in Clinical Medicine and later obtained a master’s degree in Biochemistry from the National University of Singapore in 2007.

“We are pleased to welcome Denny to Evive Biotech” said Dr. Simon Li, Chief Medical Officer of Evive Biotech. “Denny is going to lead, manage, and further grow our medical research team, especially in the US, and improve clinical trial efficiency by streamlining our medical procedures. He will also enhance internal communication with cross-functional teams and cultivate our professional relationships with external partners.”

Mr. Denny Hou commented, “I am thrilled to join the talented clinical and medical development team at Evive Biotech. I look forward to applying my knowledge in this field to assess medical and safety related events and to ensure sufficient resources for Evive’s future global clinical studies.” Mr. Hou will be based in Beijing, while operating from offices in New Jersey, San Francisco, Maryland, and Shanghai.

About Evive Biotech

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com.